NCT01684475

Brief Summary

The purpose of this study is to assess the ability of CJH1 to increase the sensitivity of dopamine receptors and thereby reduce symptoms of Parkinson's Disease.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
21

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Sep 2012

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2012

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

September 11, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 13, 2012

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2013

Completed
Last Updated

September 13, 2012

Status Verified

September 1, 2012

Enrollment Period

1 year

First QC Date

September 11, 2012

Last Update Submit

September 12, 2012

Conditions

Parkinson's Disease

Keywords

Novel Treatment Parkinson's disease

Outcome Measures

Primary Outcomes (1)

  • Reduced signs and symptoms of Parkinson's disease

    Reduced signs and symptoms of Parkinson's disease

    8 weeks

Study Arms (1)

Treatment with CJH1

EXPERIMENTAL
Drug: CJH1 (CLR4001)

Interventions

CJH1 (CLR4001)DRUG
Treatment with CJH1

Eligibility Criteria

Age40 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient's with Parkinson's disease

You may not qualify if:

  • Contraindications to study medication

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gateway Rural Health Research

Goderich, Ontario, N7A 1W5, Canada

RECRUITING

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Psychiatrist

Study Record Dates

First Submitted

September 11, 2012

First Posted

September 13, 2012

Study Start

September 1, 2012

Primary Completion

September 1, 2013

Study Completion

September 1, 2013

Last Updated

September 13, 2012

Record last verified: 2012-09

Locations

CA(1)